Draft:Nadav Ahituv
 | Review waiting, please be patient.
This may take 3 months or more, since drafts are reviewed in no specific order. There are 2,524 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Nadav Ahituv is the Director for the Institute for Human Genetics at the University of California, San Francisco (USCF).[1][2][3] He is also a Professor in the Department of Bioengineering and Therapeutic Sciences and leads the Ahituv Lab at University of California, San Francisco (USCF).[1][4]
Early Life and Education[edit]
He received his PhD with distinction in human genetics from Tel-Aviv University, where he worked on hereditary hearing loss.[1][3][2]
Research[edit]
Ahituv pioneered cis-regulation therapy (CRT) for genetic diseases that are caused due to low gene dosage and adipose manipulation transplantation (AMT) that engineers fat cells and implants them for therapeutic benefits.[5][6]
The Ahituv Lab investigates gene regulatory elements and their relationship to human diversity and disease.[4] The lab also focuses on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes, including morphological differences between species, drug response, and human disease.[7] The lab is co-developed massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements.[8]
Awards and Honors[edit]
In 2014, Ahituv received the prestigious ASCPT Leon I. Goldberg young investigator award from The American Society for Clinical Pharmacology and Therapeutics.[9][1]
References[edit]
- ^ a b c d "Nadav Ahituv | UCSF Profiles". profiles.ucsf.edu. Retrieved 2024-03-05.
- ^ a b "Nadav Ahituv". Simons Institute for the Theory of Computing. Retrieved 2024-03-05.
- ^ a b "Speaker Template". PMWC Precision Medicine World Conference. Retrieved 2024-03-05.
- ^ a b "About · Ahituv Lab". Ahituv Lab. Retrieved 2024-03-05.
- ^ Matharu, Navneet; Ahituv, Nadav (2020-11-01). "Modulating gene regulation to treat genetic disorders". Nature Reviews. Drug Discovery. 19 (11): 757–775. doi:10.1038/s41573-020-0083-7. ISSN 1474-1784. PMID 33020616. S2CID 256746336.
- ^ Matharu, Navneet; Ahituv, Nadav (2020-11-01). "Modulating gene regulation to treat genetic disorders". Nature Reviews Drug Discovery. 19 (11): 757–775. doi:10.1038/s41573-020-0083-7. ISSN 1474-1784. PMID 33020616. S2CID 256746336.
- ^ "Nadav Ahituv, PhD". UCSF Institute for Human Genetics. Retrieved 2024-03-05.
- ^ Kreimer, Anat; Ashuach, Tal; Inoue, Fumitaka; Khodaverdian, Alex; Deng, Chengyu; Yosef, Nir; Ahituv, Nadav (2022-03-21). "Massively parallel reporter perturbation assays uncover temporal regulatory architecture during neural differentiation". Nature Communications. 13 (1): 1504. Bibcode:2022NatCo..13.1504K. doi:10.1038/s41467-022-28659-0. ISSN 2041-1723. PMC 8938438. PMID 35315433.
- ^ "Nadav Ahituv, PhD | Department of Medicine". medicine.ucsf.edu. Retrieved 2024-03-05.